Novartis stock pre-market at EUR 125.02: plus 0.33 percent

Novartis stock is at EUR 125.02 pre-market at 8:29 a.m. CEST, up 0.33 percent versus the prior close. The company’s latest listed release concerns a positive European regulatory opinion for Cosentyx.

Novartis stock is at EUR 125.02 pre-market at 8:29 a.m. CEST on October 7, 2026, up 0.33 percent versus the EUR 124.61 Lang & Schwarz prior close from October 6, 2026.

Pre-market trading

The Lang & Schwarz quote shows a bid of EUR 124.38 and an ask of EUR 125.66. The further course from the Xetra open at 9:00 a.m. CET/CEST is shown by the continuously updated real-time quote of Novartis stock.

Latest company development

In its September 18, 2026 press release, Novartis said it had received a positive opinion from the European Committee for Medicinal Products for Human Use for Cosentyx in polymyalgia rheumatica. The company said the treatment could become the first IL-17A inhibitor licensed in Europe for adults with the condition.